Browse our 650+ Publications
Latest Publications
Complete loss of TP53 and RB1 is associated with complex genome and low immune infiltrate in pleomorphic rhabdomyosarcoma
Beird H et al.
HGG Advances
February 2024
Authors and Affiliates
Hannah C. Beird; Chia-Chin Wu; Michael Nakazawa; Davis Ingram; Joseph R. Daniele; Rossana Lazcano; Latasha Little; Christopher Davies; Najat C. Daw; Khalida Wani; Wei-Lien Wang; Xingzhi Song; Curtis Gumbs; Jianhua Zhang; Brian Rubin; Anthony Conley; Adrienne M. Flanagan; Alexander J. Lazar and P. Andrew Futreal.
Antigen-presenting B cells promote TCF-1+ PD1-stem-like CD8+ T-cell proliferation in glioblastoma
Hou D et al.
Frontiers in Immunology
February 2024
Authors and Affiliates
David Hou; Hanxiao Wan; Joshua L. Katz; Si Wang; Brandyn A. Castro; Gustavo I. Vazquez-Cervantes; Victor A. Arrieta; Silpol Dhiantravan; Hinda Najem; Aida Rashidi; Tzu-yi Chia; Tarlan Arjmandi; Jimena Collado; Leah Billingham; Aurora Lopez-Rosas; Yu Han; Adam M. Sonabend; Amy B. Heimberger; Peng Zhang; Jason Miska and Catalina Lee-Chang.
Immune profiling of patients with extranodal natural killer/T cell lymphoma treated with daratumumab
Qing M et al.
Annals of Hematology
February 2024
Authors and Affiliates
Min Qing; Tianyuan Zhou; Tatiana Perova; Yann Abraham; Cheryl Sweeney; Maria Krevvata; Xiaokang Zhang; Ming Qi; Grace Gao; Tae Min Kim; Ming Yao; Seok‑Goo Cho; Hyeon Seok Eom; Soon Thye Lim; Su‑peng Yeh; Yok Lam Kwong; Dok Hyun Yoon; Jin Seok Kim; Won Seog Kim; Longen Zhou; Ricardo Attar; Raluca I. Verona.
Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation
Huuhtanen, J et al.
Nature
February 2024
Authors and Affiliates
Jani Huuhtanen; Shady Adnan-Awad; Jason Theodoropoulos; Sofia Forstén; Rebecca Warfvinge; Olli Dufva; Jonas Bouhlal; Parashar Dhapola; Hanna Duàn; Essi Laajala; Tiina Kasanen; Jay Klievink; Mette Ilander; Taina Jaatinen; Ulla Olsson-Strömberg; Henrik Hjorth-Hansen; Andreas Burchert; Göran Karlsson; Anna Kreutzman; Harri Lähdesmäki and Satu Mustjoki.
Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia
Jabbour E, et al.
American Journal of Hematology
February 2024
Authors and Affiliates
Elias Jabbour1 | Gerhard Zugmaier2 | Vaibhav Agrawal3 |
Pilar Martínez-Sánchez4 | José J. Rifon Roca5 | Ryan D. Cassaday6,7 |
Boris Böll8 | Anita Rijneveld9 | Maher Abdul-Hay10 | Françoise Huguet11 |
Thomas Cluzeau12 | Mar Tormo Díaz13 | Vladan Vucinic14 |
José González-Campos15 | Alessandro Rambaldi16 | Stefan Schwartz17 |
Céline Berthon18 | Jesús María Hernández-Rivas19,20,21 | Paul R. Gordon22 |
Monika Brüggemann23 | Ali Hamidi22 | Yuqi Chen22 | Hansen L. Wong24 |
Bharat Panwar22 | Yuliya Katlinskaya22 | Ana Markovic22 | Hagop Kantarjian1
1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
2Amgen Research (Munich), GmbH, Munich, Germany
3Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope National Medical Center, Duarte,
California, USA
4Department of Hematology, Hospital Universitario 12 de Octubre, Instituto de Investigacion Sanitaria Hospital 12 de Octubre (imas12), CNIO, CIBERONC, Madrid, Spain
5Hematology and Hemotherapy Department, Clínica Universidad de Navarra, Pamplona, Spain
6Division of Hematology and Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, Washington, USA
7Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA
8First Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, University of Cologne, Cologne, Germany
9Department of Hematology, Erasmus University Medical Center Cancer Institute, Rotterdam, The Netherlands
10Perlmutter Cancer Center, New York University Langone Health, New York, New York, USA
11Department of Hematology, Institut Universitaire du Cancer-Oncopole CHU de Toulouse, Toulouse, France
12Université Nice Côte d'Azur, CHU de Nice, Nice, France
13Hematology Department, Hospital Clínico Universitario de Valencia, Instituto de Investigacion Sanitaria INCLIVA, Valencia, Spain
14Department of Hematology and Cell Therapy, University Hospital Leipzig, Leipzig, Germany
15Hematology Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain
16Department of Oncology-Hematology, University of Milan, Milan and Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy
17Department of Hematology, Oncology and Tumor Immunology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität and Humboldt-
Universität zu Berlin, Campus Benjamin Franklin, Berlin, Germany
18Centre Hospitalier Universitaire de Lille, Lille, France
19IBSAL, IBMCC, CSIC, Cancer Research Center, University of Salamanca, Salamanca, Spain
20Department of Hematology, University Hospital of Salamanca, Salamanca, Spain
21CIBERONC, Research Group CB16/12/00233, Salamanca, Spain
22Amgen Inc., Thousand Oaks, California, USA
23Department of Hematology, University of Schleswig-Holstein, Kiel, Germany
24Clinical Pharmacology, Modeling and Simulation, Amgen Inc., South San Francisco, California, USA
Isatuximab in combination with carfilzomib anddexamethasone in 1q21þ patients with relapsed/refractorymultiple myeloma: Long‐term outcomes in the Phase 3 IKEMA study
Facon T, et al.
hematological oncology
February 2024
Authors and Affiliates
Thierry Facon1 | Philippe Moreau2 | Ivan Špicka3 | Kenshi Suzuki4 |
Kwee Yong5 | Joseph Mikhael6 | Taro Fukao7 | Kamlesh Bisht7 |
Nicole M. Armstrong8 | Sandrine Macé9 | Marie‐Laure Risse10 | Thomas Martin11
1Department of Hematology, Lille University
Hospital, Lille, France
2Department of Hematology, University
Hospital Hôtel‐Dieu, Nantes, France
3Department of Hematology, 1st Faculty of
Medicine, Charles University and General
Hospital, Prague, Czech Republic
4Myeloma/Amyloidosis Center, Japanese Red
Cross Medical Center, Tokyo, Japan
5Department of Haematology, University
College Hospital, London, UK
6Translational Genomics Research Institute,
City of Hope Cancer Center, Phoenix,
Arizona, USA
7Sanofi, Global Oncology, Cambridge,
Massachusetts, USA
8Sanofi, Global Medical Affairs, Cambridge,
Massachusetts, USA
9Sanofi, Research and Development, Chilly‐
Mazarin, France
10Sanofi, Research and Development, Vitry‐
Sur‐Seine, France
11University of California San Francisco
Medical Center, San Francisco, California, USA
Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia
Stilgenbauer S, et al.
Blood Advances
January 2024
Authors and Affiliates
Stephan Stilgenbauer,1 Eugen Tausch,1 Andrew W. Roberts,2 Matthew S. Davids,3 Barbara Eichhorst,4
Michael Hallek,4 Peter Hillmen,5 Christof Schneider,1 Johannes Schetelig,6 Sebastian Böttcher,7 Arnon P.
Kater,8 Yanwen Jiang,9 Michelle Boyer,9 Relja Popovic,10 Majd T. Ghanim,10 Michael Moran,10 Wendy J.
Sinai,10 Xifeng Wang,10 Nabanita Mukherjee,10 Brenda Chyla,10 William G. Wierda,11,* John F. Seymour2,*
1Division of CLL, Internal Medicine III, Ulm University, Ulm, Germany; 2Peter MacCallum Cancer Centre,
Royal Melbourne Hospital, and University of Melbourne, Melbourne, Australia; 3Department of Medical
Oncology, Dana-Farber Cancer Institute, Boston, MA; 4Department of Internal Medicine, Center of
Integrated Oncology Köln Bonn, University Hospital of Cologne, Cologne, Germany; 5Leeds Teaching
Hospitals, NHS Trust, Leeds, United Kingdom; 6University Hospital, Technische Universität Dresden,
Dresden, Germany; 7Division of Internal Medicine, Medical Clinic III-Hematology, Oncology and Palliative
Medicine, Rostock University Medical Center, Rostock, Germany; 8Department of Hematology, Cancer
Center Amsterdam, Amsterdam University Medical Centers, Amsterdam, The Netherlands; 9Genentech,
South San Francisco, CA; 10AbbVie Inc, North Chicago, IL; 11The University of Texas MD Anderson Cancer
Center, Houston, TX
*Contributed equally.
SARS-CoV-2 vaccination in the first year after hematopoietic cell transplant or chimeric antigen receptor T cell therapy: A prospective, multicenter, observational study (BMTCTN 2101)
Hill JA, et al.
January 2024
Authors and Affiliates
Joshua A. Hill, MD; Michael J. Martens, PhD; Jo-Anne H. Young, MD; Kavita Bhavsar, MSc;
Jianqun Kou, MS; Min Chen, MS; Lik Wee Lee, PhD; Aliyah Baluch, MD; Madhav V.
Dhodapkar, MBBS; Ryotaro Nakamura, MD; Kristin Peyton, BS; Dianna S. Howard, MD; Uroosa
Ibrahim, MD; Zainab Shahid, MD; Paul Armistead, MD; Peter Westervelt, MD; John McCarty,
MD; Joseph McGuirk, DO; Mehdi Hamadani, MD; Susan DeWolf, MD; Kinga Hosszu, PhD; Elad
Sharon, MD, MPH; Ashley Spahn, BS; Amir A. Toor, MD; Stephanie Waldvogel, BS; Lee M.
Greenberger, PhD; Jeffery J. Auletta, MD; Mary M. Horowitz, MD*; Marcie L. Riches, MD;
Miguel-Angel Perales, MD
Daratumumab in Myeloma Patients With Early or Late Relapse After Initial Therapy: Subgroup Analysis of CASTOR and POLLUX.
Spencer A, et al.
Blood Advances
January 2024
Authors and Affiliates
Andrew Spencer, Philippe Moreau, M V Mateos, Hartmut Goldschmidt, Kenshi Suzuki, Mark-David Levin, Pieter Sonneveld, Robert Z Orlowski, Sung-Soo Yoon, Saad Z Usmani, Katja C Weisel, Donna Reece, Tahamtan Ahmadi, Huiling Pei, Wendy Garvin Mayo, Xue Gai, Jodi Carey, J Blake Bartlett, Robin Carson, Meletios-Athanasios A Dimopoulos